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Endemic Burkitt lymphoma (eBL) has been linked to Plasmodium falciparum (Pf ) malaria infection, but the
contribution of infection with multiple Pf genotypes is uncertain. We studied 303 eBL (cases) and 274 non
eBL-related cancers (controls) in Malawi using a sensitive and specific molecular-barcode array of 24
independently segregating Pf single nucleotide polymorphisms. Cases had a higher Pfmalaria prevalence than
controls (64.7% versus 45.3%; odds ratio [OR] 2.1, 95% confidence interval (CI): 1.5 to 3.1). Cases and controls
were similar in terms of Pf density (4.9 versus 4.5 log copies, p 5 0.28) and having $3 non-clonal calls (OR
2.7, 95% CI: 0.7-9.9, P 5 0.14). However, cases were more likely to have a higher Pf genetic diversity score
(153.9 versus 133.1, p 5 0.036), which measures a combination of clonal and non-clonal calls, than controls.
Further work is needed to evaluate the possible role of Pf genetic diversity in the pathogenesis of endemic BL.
E
ndemic Burkitt lymphoma (eBL) is a monoclonal B-cell non-Hodgkin lymphoma that is common in
equatorial Africa and Papua New Guinea, which has been linked to childhood infection with
Plasmodium falciparum (Pf)1–4, a Class 2A carcinogen for eBL5. Evidence for associations between eBL
and Pf is unclear with, for example, the risk of eBL being increased in children with antibody markers of recent Pf
infection while decreased in those with antibody markers of long-term exposure to Pf infection6,7. An alternative
approach is to assess Pf prevalence, density, or genetic diversity as risk factors for eBL. Early studies of the
association between eBL and Pf prevalence yielded null8,9 or inverse associations10, but they were limited by small
sample sizes and reliance on microscopy that has variable sensitivity to detect Pf infection and that cannot
distinguish infection with multiple Pf genotypes.
A recent ecological study using published data from Ghana, Uganda, and Tanzania11, countries where Pf
transmission intensity is moderate to high (mesoendemic to holoendemic)12–14, showed that the age-specific risk
of eBL and the average number of distinct malaria genotypes per positive blood sample both peaked between ages
5–9 years. The peaks for age-specific asymptomatic parasitaemia and parasite density, in contrast to those of eBL,
both peaked at age about 2 years12–14. Infection with multiple Pf genotypes is relatively common in children in
areas with holoendemic malaria15, but its association with eBL has yet to be fully studied.
Here, we report our investigation to test the hypothesis that Pf prevalence, parasite density in peripheral blood,
and genetic diversity are associated with eBL among 303 children with eBL (cases) compared to 274 children with
non eBL-related cancers or non-malignant conditions (controls) in Malawi. Pf genetic diversity was measured
using a sensitive and specific Pf molecular-barcode array16 of 24 independently segregating Pf single nucleotide
polymorphisms (SNPs) representative of the 3D7 Pf genome.
Results
Pfmalaria prevalence potentially associated with eBL.Cases were similar to the controls with respect to gender,
but they were slightly older than the controls (7.7 [SD 0.2] years versus 6.5 [0.3] years) (Table 1). The distribution
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of cases and controls across reported home districts was similar (not
shown). The Pf prevalence as assessed by PCR analysis was 64.7%
among the cases compared to 45.3% among the controls (OR5 2.1,
95% CI: 1.5–3.1). Similar results (66.9% versus 46.4%) were obtained
when the analysis was restricted to a subset of 239 children that were
previously tested for EBV2 (OR5 2.9, 95%, CI: 1.6–5.4). Associations
between eBL and Pf prevalence were evident after stratifying by EBV
with eBL associated with Pf among 106 children with a high EBV
antibody reactivity (OR 5 2.3, 95% CI: 0.8–6.2) and among 133
children with negative, indeterminate or low EBV reactivity (OR 5
2.5, 95% CI: 1.1–5.6).
Pf genetic diversity potentially associated with eBL. To determine
whether Pf density was associated with eBL, we compared Pf log copy
number per 105 peripheral blood mononuclear cells in cases and
controls. Log copy number of Pf parasites was similar in eBL cases
and controls (4.9 versus 4.5 log copies, p 5 0.28) and it decreased,
albeit, non-significantly with age in both groups. Pf density in
younger cases and controls (0–5 years) was 4.9 log copies and in
older children it was 4.7 log copies (p 5 0.54).
We evaluated the association between eBL and Pf genetic diversity
in a subset of 129 children that had samples with at least 2 Pf DNA
copies detected and at least 20 of 24 unambiguous SNP calls, which
we considered the threshold for valid results (Figure 1a). Although
there was no effect of Pf density on the number successful SNP calls,
there was a weak relationship between density and the proportion of
called SNPs that were non-clonal (Figure 1b) hence Pf density was
included as an adjustment in subsequent regression analyses. Genetic
diversity at one or more of the 24 SNP locations was observed in 127
(98.5%) of the 129 children (mean number of non-clonal calls per
child 11.4, standard error [se]5 0.6, Table 2). The prevalence of non-
clonal calls among cases was slightly, but not significantly, increased
compared to that among controls (RR5 1.3, 95% CI: 0.97–1.70, P5
0.08). The prevalence of cases with at least 3 non-clonal calls was 2.7
times (95% CI: 0.7–9.9, p 5 0.14) that among controls. Mixed calls
(non-concordant) may indicate presence of Pf variant strains at
levels close to the limit of assay detection. Mixed calls were less
frequent than non-clonal calls; having at least one mixed call was
observed in 80 (62%) of 129 children (Table 2). Having a mixed call
among cases was 3.2 times more likely in cases than in controls, but
the result was not statistically significant (p5 0.18). The results were
similar in an expanded subset of 160 children with at least 1 copy of
Pf DNA (Table 2).
Graphical and spline analyses of the barcode arrays of the children
ordered by either diversity score (Figure 2a, b) or by the proportion
of non-clonal SNP calls (not shown) revealed a greater preponder-
ance of cases at the more-diverse end of the Pf diversity scale.
Corroborating this finding, cases were also found to have a higher
average diversity score, which up-weighted non-clonal (scored as 10)
or mixed calls (scored as 5), than controls (mean score: 153.9
[se 5 5.8] versus 133.1 [se 5 7.7], t-test p 5 0.036) (Figure 2c).
Discussion
We report results from a case-control study of children in Malawi
evaluating whether prevalence, density or genetic diversity of
Plasmodium falciparum (Pf) might be the triggeringmalaria exposure
for children with endemic Burkitt lymphoma. Associations found
between Pf prevalence and genetic diversity with eBL agree with
the well-established epidemiology of eBL, i.e., that it occurs in rural
areas where Pf transmission is high2,4,11,17,18. The association between
eBL and Pf prevalence and genetic diversity score, although modest,
was robust in analyses adjusting for anti-EBV and anti-malaria anti-
bodies, Pf density and in sensitivity analyses. The significant differ-
ence in Pf and genetic diversity score in cases and controls supports
the hypothesis that genetic diversity of Pfmay play a role in triggering
the pathogenesis of eBL, which was based on a previous study show-
ing a correlation between age-specific peaks for number of malaria
genotypes and age-specific eBL peaks11. These results are consistent
with observations that eBL is characterized by a very short doubling
time (1–2 days)18, and that the interval from initiating or promoting
events to diagnosis may be comparatively short (3–8 months)19.
Biologically, Pf parasites and EBV are recognized as co-factors in
the genesis of eBL, but the detailed mechanisms of interaction
between Pf parasites, the B cell compartment and EBV remain
obscure. Cases in our study did not have higher average Pf density
than controls. This contrasts with children suffering from severe acute
malaria (e.g., cerebral malaria) where Pf density is high, but genetic
diversity is low20. Our results perhaps suggest a different conceptual
Table 1 | Children included in this study by cancer type showing age and sex distributions and prevalence of P. falciparum DNA and
Epstein-Barr Virus antibody in serum
Diagnosis N % Male
Age
P. falciparum
prevalence (%)
Epstein-Barr Virus antibody
Mean (se)
Classes (%)
No. Tested Prevalence (%)0–5 6–10 11–15
Cases 303 59.4 7.7 (0.2) 24.8 57.1 18.2 64.7 127 59.8
Controls 274 55.8 6.5 (0.3) 48.2 28.5 23.4 45.3 112 26.8
Diagnosis of controls
Leukemias 9 22.2 8.8 (1.6) 33.3 0.0 66.7 77.8 5 20.0
Lymphomas 51 62.7 9.3 (0.5) 13.7 43.1 43.1 47.1 16 50.0
Cranial tumours 3 66.7 9.0 (1.5) 0.0 66.7 33.3 0.0 1 0.0
Neuroblastoma 15 73.3 5.5 (1.0) 60.0 33.3 6.7 53.3 5 60.0
Retinoblastoma 14 35.7 3.6 (0.6) 92.9 0.0 7.1 64.3 10 10.0
Renal Tumours 77 57.1 4.0 (0.3) 72.7 24.7 2.6 37.7 30 26.7
Hepatic Tumours 14 71.4 10.3 (0.9) 14.3 28.6 57.1 42.9 5 20.0
Bone Tumours 3 66.7 10.3 (2.0) 0.0 66.7 33.3 66.7 1 0.0
Soft Tissue Sarcomas 44 61.4 6.4 (0.6) 52.3 25.0 22.7 38.6 19 36.8
Germ Cell Tumours 16 37.5 5.9 (1.1) 50.0 31.3 18.8 50.0 8 0.0
Epithelial Tumours 6 33.3 9.0 (1.9) 16.7 16.7 66.7 33.3 1 0.0
Other Tumours 4 25.0 4.0 (1.5) 75.0 25.0 0.0 75.0 3 33.3
Non-Malignancies 18 50.0 7.0 (1.1) 38.9 33.3 27.8 50.0 8 0.0
Not well specified 31 51.6 8.1 (0.6) 19.4 61.3 19.4 35.5
Table abbreviation: % per cent; se standard error of the mean; 8 children with Kaposi sarcoma were included in the soft tissue sarcomas; Not well specified - children didn’t have enough information to
classify them as a specific cancer. None of the 11 Not well specified diagnosis children who are Pf positive had enough DNA to make it the restricted dataset (see table 2).
www.nature.com/scientificreports
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model to explore with the underlying molecular mechanisms linking
Pf density, genetic diversity, and host proteins in eBL pathogenesis.
Clinical data support the notion of differences in the immunopathol-
ogy of Pf in eBL compared to severe malaria. First, eBL is rare in
children aged 0–2 years, despite being the age group when children
are most vulnerable to high-density Pf parasitemia and severemalaria.
Second, multi-clonal Pf infections are frequently associated with mild
malaria among people with established disease immunity21, a property
that is closer to the risk profile for eBL than severe malaria.
Pf parasites modulate host defenses promoting both an immune-
suppression, hyper-activation (immunosubversion)22,23 and expan-
sion of atypical memory B cells24. Possibly, subversion of immunity
might be enhanced by parasite genetic diversity. If so, parasite genetic
diversity could increase susceptibility of children to EBV infection or
trigger reactivation of EBV among children with latent infection.
Additionally, polymorphic Pf-encoded ligands, such as PfEMP125,
have been shown to induce polyclonal B cell activation26, preferen-
tially of memory B cells (in which EBV persists and eBL develops)
and to rescue tonsillar B cells from apoptosis, and to reactivate latent
EBV infection27,28. If parasite genetic diversity enhances immune-
subversion during infection, potential consequences could be: the
impairment of EBV-specific T-cell response, hyper-activation of
germinal centers where c-myc/Ig chromosomal rearrangements
often occur, and increased survival of translocation-positive B cells.
Further studies investigating the role of parasite genetic diversity
based on the above points are thus needed.
Our study has some limitations. By its design, it precludes us from
distinguishing whether the association precedes or follows the
development of eBL29. The use of hospital cases and controls is a
limitation because, although a similar distribution of home districts
was observed for cases and controls it is not known how well
this captures the actual malaria exposure related to geography. The
controls were slightly younger than the cases, but this difference
would bias the study towards the null, suggesting that our results
may be conservative. Other limitations include a relatively small
sample size, particularly in subgroup analyses. A particular strength
ofmolecular bar code arraywas its design, based on 24 independently
segregating SNPs scattered across the Pf genome, which made a
direct measurement and quantification of Pf genetic diversity pos-
sible with a high degree of sensitivity and specificity. Despite this
strength, themolecular barcode arraymay not be uniformly sensitive
or specific for malaria clones at low quantities. Our results motivate
Table 2 | Number (%) of children with non-clonal and mixed calls in two nested subsets of the data showing the mean (se) numbers of both
per child
Subset Group N
Non-clonal Calls Mixed Calls
at least 1 (%) at least 3 (%) mean (se) at least 1 (%) mean (se)
At least 2 Pf DNA copies
and at least 20 SNPs
called
Cases 87 86 (99) 78 (90) 12.2 (0.8) 55 (63) 1.24 (0.13)
Controls 42 41 (98) 34 (81) 9.6 (1.0) 25 (60) 1.19 (0.18)
Total 129 127 (98) 112 (87) 11.4 (0.6) 80 (62) 1.22 (0.11)
At least 1 Pf DNA copy Cases 105 104 (99) 91 (87) 11 (0.7) 67 (64) 1.29 (0.12)
Controls 55 54 (98) 43 (78) 8.9 (0.9) 34 (62) 1.13 (0.15)
Total 160 158 (99) 134 (84) 10.3 (0.5) 101 (63) 1.23 (0.10)
Table abbreviation: % per cent; se standard error of the mean; SNP single nucleotide polymorphism
Figure 1 | The relationship between the amount of P. falciparumDNA isolated in cases and controls and (A) the proportion of SNP genotypes (out of
24 SNPs) determined and (B) the proportion of determined genotypes found to be non-clonal. The relationships are illustrated by loess fitted
curves. Amount ofDNAhas been loge-transformed. Red reference line indicates 2 copies of parasite DNApresent and blue reference line indicates 20 of 24
SNPs determined. Blue markers indicate those patients included in the ‘high quality’ subset.
www.nature.com/scientificreports
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the adaptation of recently publishedmalaria genome and thematuring
bioinformatics computational methods to integrate genomics and
proteomics30 to investigate the role of malaria genetic diversity in
carcinogenesis of eBL.
To conclude, the results of this case control study of children with
endemic Burkitt lymphoma in Malawi support the hypothesis that
infection with genetically diverse Pf parasites may be associated with
eBL. It also supports the rationale of incorporating molecular meth-
ods in the study of the pathobiology of malaria in eBL. Further work
is needed to evaluate the possible role, and the underlying molecular
mechanisms, of Pf genetic diversity in the pathogenesis of eBL.
Methods
Patients and cancer diagnoses. Participants were from a case-control study of
cancers in children aged 0 to 15 years conducted at the Queen Elizabeth Hospital in
Blantyre, Malawi, between July 2005 and August 2010 as described elsewhere2,3.
Cancers included Burkitt lymphoma, other haematological malignancies (leukaemia,
Hodgkin lymphoma), neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma,
primitive neuroectodermal tumour, and Wilms’ tumour. Eight children with Kaposi
sarcoma were included in the current study. All cancer cases were reviewed clinically
by one investigator (EM) and were confirmed by histology, cytology or other
laboratory investigations when possible. Trained nurses obtained consent and
administered a standardized questionnaire to the children or their parents or
guardians. All children were routinely tested for HIV infection. HIV positive children
were excluded from the current study. For analytic purposes, children with Burkitt
lymphoma were coded as cases and children with another diagnosis as controls. The
controls comprised children admitted to the same hospital with a wide range of both
malignant and non-malignant conditions (Table 1).
Ethics review. The study obtained ethical approval from the Oxford Tropical
Research Ethics Committee and the Malawian College of Medicine Research and
Ethics Committee and exemption from ethics review by the Office of Human Subjects
Research at the National Institutes of Health. All subjects gave written informed
consent to participate.
DNA extraction, P. falciparum barcode genotyping. DNA was extracted from
whole blood samples using QIAamp Blood DNA Kit (Qiagen, Inc., Valencia, CA)
according to well-established protocols. Genomic DNA samples (20 ng) from blood
were evaluated for Human DNA content RNAse P(ABI TaqMan 4316844, VIC) and
for Plasmodium falciparum (Pf) copy number to a 519 bp segment of PF07-0076
using semi quantitative 59nucleotidase (TaqMan)16. For each sample the PF assay
consisted of 20 ng genomic DNA, 900 nMolar forward primer (CGACCCTGA
TGTTGTTGTTGGA), 900 nMolar reverse Primer (GGCTTTTTTCCATTTCTGTA
GTTAAGATTCA), 200 nMolar FAM labeled probe (CAACAGCTCCAAAATAT),
2.5 ul 23 universal master mix (Applied Biosystems), in a final volume of 5 ul.
Samples were denatured at 95 degrees for 10 minutes followed by 40 cycles of
amplification (95 degrees 15 sec, 60 degree 60 sec) on ABI 7900HT. Human DNA
content was assessed in parallel aliquots using identical conditions and substituting
primers for the Human RNAse P gene (TaqMan 4316844, VIC, product 87 bp,). The
average cycle threshold of triplicate measurements for samples were compared to
standards of known copy number and those samples with P. falciparum DNA at
greater than 0.5 copies per sample were included in subsequent genotyping analysis.
Genotyping assays were performed in 96.96 dynamic arrays for SNP genotyping
(SNP arrays) using the BioMark platform (Fluidigm). Each sample was assayed in
quadruplicate for 24 nucleotide polymorphisms (Daniels et al, manufactured by
Fluidigm). Samples comprising 20 ng genomic DNA, 50 nMolar STA primer mix-
ture, 50 nMolar LSP Primer mixture 2.5 ul 23 universal master mix (Applied
Biosystems), in a final volume of 5 ul. Samples were denatured at 95 degrees for 10
minutes followed by 15 cycles of amplification (95 degrees 15 sec, 60 degrees 120 sec)
on ABI 9700. The Fluidigm SNPArraymicrofluidic chips were loaded with 5 ul assay
comprising 2.5 mL assay loading reagent (23) (Fluidigm 85000736), 1.0 mL 503 SNP
genotyping assay mix, 7.5 uM each allelic specific primer and 20 uM locus specific
primer) and 1.5 mL RNAse/DNAse free water. Samples were loaded in (5 mL) com-
prising 2.5 mL Biotium 23 Fast Probe master mix (Biotium 31005) 0.25 mL SNPtype
sample loading reagent (203) (Fluidigm 100-3425), 0.08 ul SNPtype Reagent
(Fluidigm 100-3402), 0.03 ul ROX (Invitrogen 12223-012), 0.06 mL RNAse/DNAse
free water, and 2.08 ul 5-fold dilution of the pre-amplification mixture. Control
samples included a negative control (2.08 ul of water instead of genomic DNA) and
positive controls of malaria genomic DNA samples (MRA-102G, MRA-150G, MRA-
205G, MRA-330G) from BEI resources (Manassas, Virginia). Individual assays
(5 mL) and samples (5 mL) was pipetted into separate inlets on the frame of the SNP
arrays per the manufacturer instructions. Microfluidic chip loading and mixing of
samples and assay mixtures in the 9216 reaction chambers of the dynamic array was
carried out on the IFC Controller HX. PCR and image processing was carried out on
the BioMark system (Fluidigm). Laboratory staff were masked to the case or control
status of the samples.
Two issues surrounding the analyses of the SNP results were identified. Firstly,
there were a number of SNP calls that were discordant when the assay was repeated:
one time clonal and another non-clonal. This ambiguity might be taken as an indi-
cator of a mixed infection where one clone is at the limit of detectability. Secondly,
successful allelic Pf typing was defined as classification of at least 20 of the 24 SNPs on
the malaria barcode at a threshold at 2 copies of Pf DNA in the sample. The pro-
portion of samples with determined genotypes declined rapidly below this threshold
(Figure 1a).
Statistical analyses. Initial descriptive analyses of the complete sample of 577 patients
were carried out and associations between having Burkitt lymphoma or any other
cancer and the presence of P. falciparum and/or EBV were assessed using logistic
regression adjusted for age, sex and month and year of enrolment.
Figure 2 | The genetic diversity of P. falciparum isolates from 87 cases and 42 controls. A) The barcode array: The barcode for a single patient is
represented in a single rowwhilst each column summarizes the diversity at each SNP location. Cases and controls are ordered by the diversity score (most
diverse are at the bottom of the plot) and the SNPs are arranged by location in the P. falciparum genome – the first column indicating cancer diagnosis
(Cases in red and controls in blue). SNP results are coded as follows:minor allele as lighter blue,major allele as darker blue, potentiallymixed call as lighter
green, non-clonal call as darker green and a failed call as light gray. B) A loess spline curve relating diversity score to the probability of being a case. The X
symbols mark the rows for controls and small circles mark the rows for cases. C) A comparison of the distributions of the diversity score among cases and
controls.
www.nature.com/scientificreports
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Themain analyses of clonality were restricted to samples with at least 2 copies of Pf
DNA and calls for at least 20 of the 24 barcode loci. Firstly, the number of non-clonal
calls among cases and controls was compared using a negative binomial regression
model using the number of SNP calls made as an offset (natural logarithm (loge)-
transformed)) and adjusted for age, sex, year andmonth of enrolment and amount of
Pf DNA present. A similar approach was used to assess the number of potentially
mixed calls that occurred. Logistic regressions of the presence of at least one poten-
tially mixed call or at least 3 non-clonal calls were also carried out. These analyses
were repeated in sensitivity analyses including 160 participants with at least 1 copy of
Pf DNA.
Finally, the unique barcode array for cases and controls was assembled and
potential clustering of barcodes assessed by relating the array to cancer type status
using a spline fit (with 95% confidence limits). A binary cancer type code was con-
sidered the outcome while the array was considered the predictor. The barcodes were
ordered in two ways. First, a ‘genetic diversity’ score was assigned to each possible
SNP call at each of the 24 locations: 0 for a failed call, 1 for a minor allele (,35%
prevalence, as previously defined by Daniels et al16,31), 3 for a major allele, 5 for a
potentially mixed call and 10 for a non-clonal call. The score for the entire array was
obtained by summing these scores. Second, the proportion of the array with non-
clonal calls was determined. For this, potentially mixed calls counted as both a clonal
call and non-clonal call. Departures of the spline fit away from the proportion of
patients in the sample with Burkitt lymphoma may be indicative of clusters of bar-
codes predominantly found in one group of patients. Two-sided p-values,0.05 were
considered statistically significant; p-values between 0.1 and 0.05 were suggestive of a
trend. Because this study was exploratory in nature for hypothesis generation, no
adjustment was done for multiple comparisons. All analyses were undertaken with
the SAS System (SAS/STAT version 12.3, SAS Institute, Cary, NC, USA).
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